This clinical quality registry aims to improve myeloma outcomes by providing an evidence base for the best strategies to diagnose, treat and support people with myeloma and related diseases.
Patients accrued
Patients with multiple myeloma
Number of approved sites
M1000 Biobank participants
The MRDR Annual Breakfast Meeting 2026 recording is now available to view.
Read moreJoin us for presentations using MRDR data and visit the Monash University booth - Blood 2026 Exhibition Hall Booth 012. We'd love to chat about the registry, answer any questions or just to come say hi!
Read moreMonday 19 October, 7.00am NZDT, Weta Uncorked, Auckland, New Zealand
Read moreNew research using MRDR data explores toxicity-related treatment cessation and survival outcomes in newly diagnosed multiple myeloma patients.
Read more
